MYL3 and breast carcinoma: The final results established that the cMLC-1 level was significantly higher in plasma of patients with breast cancer than in normal donors (63.18 ± 55.31 ng/mL vs. 37.61 ± 35.39 ng/mL, p=0.0006) (Figure 2A).